|[July 17, 2014]
Integral Molecular Announces Patent Allowance for Dengue Research Technology
PHILADELPHIA --(Business Wire)--
Integral Molecular, a leader in membrane protein research, announces the
issuance of a new composition patent protecting dengue reporter virus
particles (RVPs). The invention relates to the company's chimeric and
codon-optimized flavivirus replicons, expression plasmids, and RVPs used
for infectivity, neutralization, enhancement and structure-function
studies of dengue virus (DENV) and its envelope protein (prM/E). U.S.
Patent No 8,691,961, was issued by the USPTO on April 8, 2014,
furthering the company's commitment to the discovery of drugs and
vaccines against this widespread virus.
"The dengue virus RVPs are enabling faster and more accurate
quantification of dengue sera and antibody neutralization and
enhancement," said Benjamin Doranz, Chief Scientific Officer at Integral
Molecular. "The technology is also being used in our structural studies
of DENV envelope, for instance, to identify the exact residues
responsible for mediating its folding, triggering, and fusion."
Integral Molecular has a long standing interest in dengue research, and
has epitope mapped over 150 monoclonl antibodies targeting dengue
envelope proteins as part of an ongoing contract funded by the National
Institute of Allergy and Infectious Diseases (NIAID). This work has been
described in numerous publications, including seven publications in the
past two years, providing important insights into the functionality of
DENV prM/E. Viral epitopes were mapped using the company's Shotgun
Mutagenesis technology which enables vaccine researchers to identify
immunodominant regions of a target pathogen. Integral Molecular has
similarly used its Shotgun Mutagenesis technology to map antibody
epitopes on diverse viral pathogens, including chikungunya, hepatitis B,
hepatitis C, HIV, and respiratory syncytial viruses.
Integral Molecular offers dengue virus RVPs that retain antigenic
equivalence to wild-type virions by incorporating prM/E proteins from
DENV serotypes 1, 2, 3, or 4. DENV RVPs feature a reporter gene that
provides a rapid and convenient read-out of infectivity, and are
validated for both antibody neutralization and enhancement studies.
Epitope mapping of anti-viral antibodies by Shotgun Mutagenesis is
offered on a fee-for-service basis.
About Integral Molecular
Integral Molecular is a research-driven biotechnology company committed
to providing innovative solutions for therapeutic antibody discovery
involving integral membrane proteins. Over the last decade, the company
has been working with pharmaceutical, biotechnology and academic
customers and collaborators, providing membrane protein solutions that
advance its customers' scientific objectives.
For more information please visit the reporter virus section of Integral
Molecular's website: www.integralmolecular.com/application-notes.php#tab_reporterViruses
[ InfoTech Spotlight's Homepage ]